플러스100%마이너스

  • 화면크기
통합검색

한의약융합데이터센터


근거중심한의약 DB

Home > 한의약융합데이터센터 > 근거중심한의약 DB
Title

Evaluation of a multi-herb supplement for erectile dysfunction: a randomized double-blind, placebo-controlled study.

Authors

Shah GR, Chaudhari MV, Patankar SB, Pensalwar SV, Sabale VP, Sonawane NA.

Journal

BMC Complement Altern Med.

Year

2012

Vol (Issue)

12

Page

155.

doi

10.1186/1472-6882-12-155.

PMID

22978405

Url

http://www.ncbi.nlm.nih.gov/pubmed/22978405

MeSH

Adult
Double-Blind Method
Erectile Dysfunction/blood
Erectile Dysfunction/drug therapy*
Erectile Dysfunction/psychology
Humans
India
Male
Middle Aged
Patient Satisfaction
Plant Extracts/adverse effects
Plant Extracts/therapeutic use*
Plants, Medicinal/chemistry*
Semen Analysis
Testosterone/blood
Treatment Outcome
Young Adult

Keywords

한글 키워드

KMCRIC
Summary & Commentary

KMCRIC 비평 보기 +

Korean Study

Abstract

BACKGROUND:
Evidence is lacking for multi-ingredient herbal supplements claiming therapeutic effect in sexual dysfunction in men. We examined the safety and efficacy of VigRX Plus (VXP) - a proprietary polyherbal preparation for improving male sexual function, in a double blind, randomized placebo-controlled, parallel groups, multi-centre study.
METHODS:
78 men aged 25-50 years of age; suffering from mild to moderate erectile dysfunction (ED), participated in this study. Subjects were randomized to receive VXP or placebo at a dose of two capsules twice daily for 12 weeks. The international index of erectile function (IIEF) was the primary outcome measure of efficacy. Other efficacy measures were: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS), Serum testosterone, Semen analysis, Investigator's Global assessment and Subjects' opinion.
RESULTS:
In subjects receiving VXP, the IIEF-Erectile Function (EF) scores improved significantly as compared to placebo. After 12 weeks of treatment, the mean (sd) IIEF-EF score at baseline increased from 16.08 (2.87) to 25.08 (4.56) in the VXP group versus 15.86 (3.24) to 16.47 (4.25) in the placebo group (P < 0.0001). Similar results were observed in each of the remaining four domains of the IIEF (orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction).There was a significant difference for VXP versus placebo comparison of mean (sd) EDITS scores of patients: 82.31(20.23) vs 36.78(22.53) and partners :(82.75(9.8) vs 18.50(9.44);P < 0.001. Thirty-five out of 39 (90%) subjects from the VXP group and one (3%) from the placebo group wished to continue with the treatment they received. Investigator's global assessment rated VXP therapy as very good to excellent in more than 50% patients and placebo therapy as fair to good in about 25% of patients. Incidence of side effects and subject's rating for tolerability of treatment was similar in both groups.
CONCLUSIONS:
VigRX Plus was well tolerated and more effective than placebo in improving sexual function in men.
TRIAL REGISTRATION:
Clinical Trial Registry India, CTRI/2009/091/000099, 31-03-2009.

국문초록

Language

영어

첨부파일